Forwarded from 바이오스펙테이터
Alteogen Finally Reveals Partner as MSD, Strikes Additional $450M Deal for Keytruda SC
Alteogen announced on the 22nd that it signed a contract with Merck (MSD) of the United States for the human hyaluronidase-based platform subcutaneous administration (SC) modification technology ‘ALT-B4’. In addition to the existing contract, it is a deal worth a total of $452 million, including a down payment of $20 million and a milestone increase.
http://m.biospectator.com/view/news_view.php?varAtcId=21169
Alteogen announced on the 22nd that it signed a contract with Merck (MSD) of the United States for the human hyaluronidase-based platform subcutaneous administration (SC) modification technology ‘ALT-B4’. In addition to the existing contract, it is a deal worth a total of $452 million, including a down payment of $20 million and a milestone increase.
http://m.biospectator.com/view/news_view.php?varAtcId=21169
바이오스펙테이터
Alteogen Finally Reveals Partner as MSD, Strikes Additional $450M Deal for Keytruda SC
Alteogen announced on the 22nd that it signed a contract with Merck (MSD) of the United States for the human hyaluronidase-based platform su
Forwarded from 재야의 고수들
Forwarded from 고 래
https://naver.me/Fx98xxqs
다이이찌산쿄의 ADC 매출은 2029년까지 100억달러를 돌파할 것이라는 전망이다. 같은 기간 씨젠(Seagen)과 로슈(Roche)의 매출은 각각 58억달러와 36억달러로 전망됐다.
다이이찌산쿄의 ADC 매출은 2029년까지 100억달러를 돌파할 것이라는 전망이다. 같은 기간 씨젠(Seagen)과 로슈(Roche)의 매출은 각각 58억달러와 36억달러로 전망됐다.
👍1